This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
FMDV 3C
From Proteopedia
(Difference between revisions)
| Line 11: | Line 11: | ||
== Relevance == | == Relevance == | ||
Vaccines against FMDV are used where the disease is endemic, however, vaccination is not permitted in many countries due to the potential risk for the escape of FMDV. Therefore, there has been interest in producing empty capsid particles for use of potential vaccines against FMD. | Vaccines against FMDV are used where the disease is endemic, however, vaccination is not permitted in many countries due to the potential risk for the escape of FMDV. Therefore, there has been interest in producing empty capsid particles for use of potential vaccines against FMD. | ||
| - | Unfortunately, there has been a number of challenges in this synthetic approach, due to 3C's toxicity to cells making it difficult to produce large amounts of processed | + | Unfortunately, there has been a number of challenges in this synthetic approach, due to 3C's toxicity to cells making it difficult to produce large amounts of processed capsid proteins. |
| - | To solve this conundrum, different strategies must be analyzed to determine an optimal system for the production of FMDV empty capsid proteins with a limited amount of 3C protease that can stll process P1-2A, with out adverse expression effects. | + | To solve this conundrum, different strategies must be analyzed to determine an optimal system for the production of FMDV empty capsid proteins with a limited amount of 3C protease that can stll process P1-2A, with out adverse expression effects. Low levels of 3C expression can be achieved by making mutations, which can then be tested through western blot to see if it is sufficient enough to process P1-2A. |
== Structural highlights == | == Structural highlights == | ||
<scene name='70/702408/Fmdv_3c_protease_type_a10/6'>FMDV 3C Protease</scene> | <scene name='70/702408/Fmdv_3c_protease_type_a10/6'>FMDV 3C Protease</scene> | ||
Revision as of 15:08, 14 July 2015
FMDV 3C Protease
| |||||||||||
References
references [1]


